Early Ph IIa study of ATI-450 (Zunsemetinib), an investigational selective MAP kinase–2 (MK2) blocker leds to a sustained antiinflammatory effect; studied in 19 RA pts w/ ACR 20/50/70 of 60%/33%/20% at wk 12. https://t.co/IyjJCgdXG2